Nilotinib Aenorasis (Nilotinib)

Nilotinib selectively blocks the activity of the BCR‑ABL tyrosine kinase as well as PDGFR and c‑KIT receptors. By inhibiting these enzymes, it disrupts signaling pathways essential for the proliferation and survival of leukemic cells, leading to reduced tumor growth and disease control.

The dose of Nilotinib Aenorasis is determined by the prescribing physician based on the patient’s specific condition, disease phase, and clinical response. Dosing recommendations are provided in the product’s prescribing information and should not be altered without medical guidance.

Safety of nilotinib in pregnancy and lactation has not been established. The drug is classified as contraindicated or to be used only if the potential benefit justifies the risk. Women of childbearing potential should use effective contraception, and breastfeeding is generally discouraged while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Both nilotinib and imatinib inhibit BCR‑ABL, but nilotinib is a second‑generation inhibitor with higher potency and activity against many imatinib‑resistant mutations. Clinical studies show faster and deeper molecular responses with nilotinib, though safety profiles differ, requiring distinct monitoring for cardiac and metabolic effects.

Store the tablets at ambient temperature, preferably below 25 °C, in the original blister pack to protect from moisture and light. Keep the product out of reach of children and avoid exposure to excessive heat or humidity, which could compromise tablet integrity.

Nilotinib Aenorasis is taken orally, usually with a full glass of water. The prescribing information advises taking the medication on an empty stomach—typically one hour before or two hours after a meal—to ensure consistent absorption. Swallow tablets whole; do not crush or chew them.

The most critical risks include QT interval prolongation leading to potentially life‑threatening arrhythmias, arterial occlusive events such as heart attack or stroke, severe liver toxicity, pancreatitis, and serious skin reactions like Stevens‑Johnson syndrome. Patients should report any chest pain, palpitations, jaundice, severe abdominal pain, or skin blistering promptly.

Nilotinib is contraindicated in patients with a known hypersensitivity to the drug or any of its excipients. It should also be avoided in individuals with a history of significant QT prolongation, uncontrolled cardiac disease, or severe hepatic impairment unless a specialist determines that benefits outweigh risks.